Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Pulmonx Corporation Common Stock

LUNG

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Last trade $2.70
Day change -$0.10 (-3.57%)
Day range $2.58 – $2.81
Volume 590,479
Market cap $122M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$121.94M
Price / earnings
—
Price / book
3.57×
Price / sales
1.37×
EV / sales
1.21×
EV / EBITDA
-2.78×

Profitability

Earnings per share
-$0.98
Return on assets
-38.61%
Return on equity
-124.42%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.11×
Current ratio
4.05×
Quick ratio
3.31×
Cash ratio
2.54×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LUNG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$22.84M$22.76M$20.59M$22.6M$21.5M$23.86M$22.54M$23.77M
Cost of revenue$5.44M$5.01M$4.54M$5.06M$5.45M$6.66M$6.2M$6.18M
Gross profit$17.4M$17.74M$16.04M$17.54M$16.05M$17.2M$16.34M$17.59M
Selling, general and administrative$20.03M$21.77M$24.1M$22.86M$25.6M$26.7M$26.15M$27.01M
Research and development$4.86M$5.03M$4.9M$4.58M$4.85M$5.31M$4.76M$4M
Total operating expenses$24.89M$26.8M$29M$27.44M$30.45M$32.01M$30.91M$31.01M
Operating income-$7.49M-$9.06M-$12.96M-$9.9M-$14.39M-$14.8M-$14.56M-$13.42M
Interest expense-$1.23M-$1.22M-$976K-$770K-$805K-$799K-$781K-$842K
Income before taxes-$8.24M-$9.95M-$13.51M-$10.24M-$13.83M-$15M-$14.31M-$13.14M
Income taxes$151K$133K$149K$186K$128K$177K$135K$38K
Net income-$8.39M-$10.08M-$13.65M-$10.43M-$13.96M-$15.17M-$14.45M-$13.18M
Net income attributable to common shareholders-$8.39M-$10.08M-$13.65M-$10.43M-$13.96M-$15.17M-$14.45M-$13.18M
EBITDA-$7.28M-$8.84M-$12.74M-$9.67M-$14.15M-$14.51M-$14.29M-$13.12M
Basic earnings per share-$0.19-$0.24-$0.33-$0.25-$0.34-$0.38-$0.36-$0.33
Diluted earnings per share-$0.19-$0.24-$0.33-$0.25-$0.34-$0.38-$0.36-$0.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Pulmonx: 3 Key Takeaways for Long-Term Investors

Pulmonx returned to year-over-year top-line growth with $22.8 million in Q3 2026 revenue, driven by cost reductions that cut operating expenses 18% YoY and focused commercial execution. The company reduced full-year cash burn expectations to $22 million and maintains gross margins above 75%, with management confident in a clear pathway to cash flow breakeven. Market expansion through AeriSeal trials could expand the addressable market by roughly 20% globally.

Zacks Investment Research

All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy

Pulmonx Corporation (LUNG) has been upgraded to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at -$0.98 per share, but analysts have raised estimates by 7.6% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals.

Zacks Investment Research

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) reported a quarterly loss of $0.19 per share, beating the consensus estimate of $0.26 loss and representing a 26.92% earnings surprise. The company posted revenues of $22.84 million, surpassing consensus by 3.75%. However, shares have underperformed the market, down 11.8% year-to-date versus the S&P 500's 12.1% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%

The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.